SCHEMBL12552172

SCHEMBL12552172

Ic1cnn(C2CCCCO2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 1/20 0.43
KDM5B Q9UGL1 1/20 0.42
ALDH1A1 P00352 3/20 0.38
LMNA P02545 2/20 0.38
POLB P06746 2/20 0.38
CYP4F2 P78329 4/20 0.35
CYP4A11 Q02928 4/20 0.35
MCL1 Q07820 1/20 0.35
FLT3 P36888 2/20 0.33
SYK P43405 1/20 0.33
AURKB Q96GD4 1/20 0.33
CYP2C19 P33261 1/20 0.33
FGFR1 P11362 2/20 0.33
FGFR2 P21802 1/20 0.33
FGFR4 P22455 1/20 0.33
FGFR3 P22607 1/20 0.33
KDR P35968 1/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29159596 0.95 MPO (0.44) MPOKDM5BALDH1A1LMNAPOLB
SCHEMBL20661128 0.82 KDM5B (0.43) KDM5BALDH1A1LMNAPOLBCYP4F2
SCHEMBL584036 0.80 KDM5B (0.40) KDM5BALDH1A1LMNAPOLBCYP4F2
SCHEMBL1565909 0.80 KDM5B (0.42) KDM5BALDH1A1LMNAPOLBCYP4F2
SCHEMBL1128591 0.80 KDM5B (0.40) KDM5BALDH1A1LMNAPOLBCYP4F2
SCHEMBL20380105 0.80 KDM5B (0.40) KDM5BALDH1A1LMNAPOLBCYP4F2
SCHEMBL16353569 0.80 ALDH1A1 (0.44) KDM5BALDH1A1LMNAPOLBCYP4F2
SCHEMBL21962281 0.80 CYP4F2 (0.40) KDM5BALDH1A1LMNAPOLBCYP4F2
SCHEMBL20237038 0.80 KDM5B (0.40) KDM5BALDH1A1LMNAPOLBCYP4F2
SCHEMBL15607370 0.80 KDM5B (0.40) KDM5BALDH1A1LMNAPOLBCYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528831-B1 Layered metal-organic framework material and preparation method and use thereof BEIJING UNIVERSITY OF TECHNOLOGY (CN) 2026-01-20 US claimed
CN-117659430-B Layered metal organic framework material, preparation method and application 北京工业大学 2025-06-17 CN claimed
CN-119490480-A Isophenyl bridged alkynyl pyrazole pyridine derivative and preparation method and application thereof 北京工业大学 2025-02-21 CN claimed
CN-117659430-A Layered metal organic framework material, preparation method and application 北京工业大学 2024-03-08 CN claimed
WO-2026105055-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF ANIMOL DISCOVERY, INC (US) 2026-05-21 WO disclosed
US-20260116881-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS INC (US) 2026-04-30 US disclosed
US-20260085061-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2026-03-26 US disclosed
US-12528831-B1 Layered metal-organic framework material and preparation method and use thereof BEIJING UNIVERSITY OF TECHNOLOGY (CN) 2026-01-20 US disclosed
US-12448367-B2 Phthalazine derivatives as pyruvate kinase modulators SITRYX THERAPEUTICS LIMITED (GB) 2025-10-21 US disclosed
EP-4612132-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS Sitryx Therapeutics Limited (GB) 2025-09-10 EP disclosed
US-12404261-B2 Compounds and compositions for treating conditions associated with cGAS NOVARTIS AG (CH) 2025-09-02 US disclosed
EP-3980412-B1 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2025-08-13 EP disclosed
US-20160038486-A1 DRUG FOR RESPIRATORY DISEASES DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-02-11 US disclosed
EP-2974730-A1 DRUG FOR RESPIRATORY DISEASES DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-20 EP disclosed
EP-2813491-A1 CYCLOALKANE DERIVATIVE Daiichi Sankyo Co., Ltd. (JP) 2014-12-17 EP disclosed
US-8889741-B2 Cycloalkane derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-11-18 US disclosed
US-20140045862-A1 Cycloalkane Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-02-13 US disclosed
EP-2299824-B1 PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME (US) 2013-06-19 EP disclosed
US-20110144056-A1 PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-06-16 US disclosed
US-20110144056-A1 PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116881-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE KIF2C, KIF5B, KIF5C MPO 4731/4885KDM5B 2611/4885ALDH1A1 2556/4885
US-12404261-B2 Compounds and compositions for treating conditions associated with cGAS CGAS, TDP1, IAPP MPO 233/4885KDM5B 4786/4885ALDH1A1 2159/4885
US-20260085061-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS PDK1, PDK2, PDK4 MPO 3489/4885KDM5B 1311/4885ALDH1A1 629/4885
US-20110144056-A1 PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH FAAH, FAAH2, HRH2 MPO 3518/4885KDM5B 755/4885ALDH1A1 1185/4885
US-20160038486-A1 DRUG FOR RESPIRATORY DISEASES SCN1B, NHERF1, SCNN1A MPO 1845/4885KDM5B 4800/4885ALDH1A1 641/4885
US-20140045862-A1 Cycloalkane Derivatives TRPV1, TRPA1, SCNN1A MPO 1590/4885KDM5B 4754/4885ALDH1A1 718/4885
US-12528831-B1 Layered metal-organic framework material and preparation method and use thereof HAO2, CTNND1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MPO 636/4885KDM5B 1677/4885ALDH1A1 3223/4885
US-12448367-B2 Phthalazine derivatives as pyruvate kinase modulators PDK1, PDK2, PDK3 MPO 3328/4885KDM5B 1880/4885ALDH1A1 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.